eli lilly tirzepatide trial Shows Superiority in SURMOUNT-3 and 4 Tirzepatide Delivers in SURMOUNT-2 -
Description
Starting at $5/day
The SURPASS-1 to -5 clinical trials assessed the efficacy of once weekly tirzepatide (5, 10 and 15 mg) versus placebo or active comparators (semaglutide 1 mg, insulin degludec and insulin glargine) in T2D
Recent Findings GLP-1 RAs effectively induce weight loss
A new study shows that more Americans are choosing GLP-1 medications over bariatric surgery, but insurance coverage in Louisiana complicates that choice.
In particular, incretin-based therapies and sodium-glucose co-transporter 2 (SGLT2) inhibitors have attracted increasing interest not only for their glucose-lowering effects, but also for their broader metabolic, renal, and cardiovascular benefits
